Navigation Links
FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
Date:8/25/2011

erse reactions reported in at least 1% of patients included fever, transaminase increase, dizziness, and rash.  

Full U.S. prescribing information for FIRAZYR will be available at http://www.FIRAZYR.com. For more information about HAE visit http://www.haea.org. Prescribing information may differ between countries. Please consult your local prescribing information.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine, as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of th
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
2. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
3. FDA Approves Fougeras Clotrimazole Cream USP 1%
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
8. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
9. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
10. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
11. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Iowa , Sept. 30, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... States Patent and Trademark Office (USPTO) issued U.S. ... application entitled, "Benzoic Acid, Benzoic Acid Derivatives and ... of Making and Use Thereof." The ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Seamless Performance Between GeneChip Scanner 3000 ... , ... GeneChip Instrument System is the most advanced microarray analysis platform ... array manufacturing processes have enabled Affymetrix to produce expression probe arrays with ...
... Spectrometry Application Note , Melissa ... Introduction , ... complex mixtures is one of the key objectives for the use of ... ion trap systems, such as the Finnigan LCQ Deca XP Plus and ...
... Chromatography and Mass Spectrometry Application Note , ... Quantum Discovery Enhanced Mass- Resolution , Xiaoying ... Walter Korfmacher 1 , ... NJ, USA; 2 Thermo Electron Corporation, Somerset, NJ, USA , ...
Cached Biology Technology:The New Affymetrix GeneChip Scanner 3000 2The New Affymetrix GeneChip Scanner 3000 3The New Affymetrix GeneChip Scanner 3000 4The New Affymetrix GeneChip Scanner 3000 5The New Affymetrix GeneChip Scanner 3000 6The New Affymetrix GeneChip Scanner 3000 7The New Affymetrix GeneChip Scanner 3000 8The New Affymetrix GeneChip Scanner 3000 9The New Affymetrix GeneChip Scanner 3000 10The New Affymetrix GeneChip Scanner 3000 11The New Affymetrix GeneChip Scanner 3000 12The New Affymetrix GeneChip Scanner 3000 13The New Affymetrix GeneChip Scanner 3000 14The New Affymetrix GeneChip Scanner 3000 15Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 2Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 3Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 5Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 6
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... Medicine reports positive results of a phase 1 ... of lung cancer marked by rearrangement of the gene ... advanced non-small cell lung cancer testing positive for ROS1 ... 3 complete responses and 33 partial responses. Median progression-free ... to resume its growth after being slowed by treatment ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... little research has been done on it, now may have ... involving people, the acai (ah-sigh-EE) berry has proven its ability ... as juice and pulp. That finding, by a team of ... of the Journal of Agricultural and Food Chemistry ., ...
... a chance to take root and spread, scientists are ... prevention. Leading experts from around the globe are gathering ... promising new field, with the hope this work will ... you take advantage of the meeting,s scientific abstracts and ...
... al.report in the Journal of Cell Biology ... movement in tumor cells., On 2D surfaces, cells may ... the cell to the extracellular matrix, are known to ... been unclear. Recent work has suggested that an integrin ...
Cached Biology News:Research shows Brazilian acai berry antioxidants absorbed by human body 2Research shows Brazilian acai berry antioxidants absorbed by human body 3